Conditioning with oral busulfan with fludarabine or oral busulfan and cyclosphosphamide in patients with chronic myeloid leukaemia, chronic phase, using sibling donor: experience of coorporative group (Caipira Connection) in Brazil

被引：0
|
作者：
Colturato, V. A. R. [1 ]
Mauad, M. A. [1 ]
Souza, M. P. [1 ]
Machado, C. M. [1 ]
Paton, E. J. A. [2 ]
Pontes, E. R. [3 ]
Voltareli, J. C. [4 ]
Simoes, B. P. [4 ]
Machado, P. E. A. [1 ]
机构：
[1] Hosp Amaral Carvalho, Jau, Brazil
[2] Hosp Pio 12, Barretos, Brazil
[3] HC Sao Jose do Rio Preto, Sao Jose Do Rio Preto, Brazil
[4] HC USP Ribeirao Preto, Ribeirao Preto, Brazil
来源：
BONE MARROW TRANSPLANTATION | 2008年 / 41卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S307 / S307
页数：1
相关论文
共 19 条
  • [1] Alternative donor hematopoietic stem cell transplantation using busulfan, fludarabine, and thymoglobulin conditioning for patients with chronic granulomatous disease
    Hee, Y. Keon
    Sang, Y. Eun
    Seounghee, J.
    Yae-Jean, K.
    Suk, K. Eun
    Won, L. Ji
    Woong, S. Ki
    Hoe, K. Hong
    BONE MARROW TRANSPLANTATION, 2017, 52 : S481 - S482
  • [2] Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation
    Truscott, Laurel
    Pariury, Holly
    Hanmod, Santosh
    Davini, Monica
    de la Maza, Michelina
    Sapp, Lauren N.
    Staples, Kyleigh
    Proytcheva, Maria
    Katsanis, Emmanuel
    PEDIATRIC BLOOD & CANCER, 2023, 70 (02)
  • [3] Reduced-intensity conditioning stem cell transplantation with allogeneic blood fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning
    Martino, R
    Pérez-Simón, JA
    Moreno, E
    Queraltó, JM
    Caballero, D
    Mateos, M
    Sureda, A
    Cañizo, C
    Brunet, S
    Briones, J
    Vazquez, L
    Clopés, A
    San Miguel, JF
    Sierra, J
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (06) : 437 - 447
  • [4] High incidences of acute and chronic graft-versus-host disease after haematopoietic cell transplants for acute myeloid leukaemia using thiotepa, busulfan and fludarabine pretransplant conditioning
    Halahleh, Khalid
    Makoseh, Mohammad
    Sultan, Iyad
    Al Rimawi, Dalia
    Muradi, Isra
    Gale, Robert
    ACTA HAEMATOLOGICA, 2023, 146 (01) : 88 - 91
  • [5] Relapse following busulfan/cyclophosphamide conditioning in children and adolescents undergoing hla-identical sibling transplantation for stable phase chronic myeloid leukemia
    Lehmann, L. E.
    Buonanno, M.
    Duncan, C. N.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) : 62 - 63
  • [6] Allogeneic haematopoietic cell transplantation using reduced-intensity conditioning with intravenous busulfan plus fludarabine in acute myeloid leukaemia. Results in 50 patients not eligible for myeloablative conditioning
    Serrano, D.
    Sanz, J.
    Sanchez, J.
    Duarte, R.
    Barrenetxea, C.
    Sampoll, A.
    Gonzalez, M.
    Figuera, A.
    Varela, R.
    Diez-Martin, J. L.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S294 - S295
  • [7] Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine as conditioning regimen for matched sibling and unrelated donor transplant in patients with acute myeloid leukemia in fist complete remission. A study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)
    Saraceni, F.
    Labopin, M.
    Hamladji, R-M
    Mufti, G.
    Socie, G.
    Shimoni, A.
    Delage, J.
    Deconinck, E.
    Chevallier, P.
    Blaise, D.
    Sanz, J.
    Huynh, A.
    Forcade, E.
    Savani, B.
    Mohty, M.
    Nagler, A.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S70 - S70
  • [8] HIGH RATE OF DE NOVO CHRONIC GRAFT-VERSUS-HOST (CGVHD) FOLLOWING BUSULFAN-FLUDARABINE CONDITIONING AND ALLOGENEIC STEM CELL TRANSPLANTATION FROM A MATCHED-SIBLING DONOR (MSD) FOR AML/MDS
    Saliba, R. M.
    Komanduri, K., V
    Koca, E.
    Alousi, A. M.
    Giralt, S.
    Andersson, B. S.
    Zhang, W.
    Rondon, G.
    Neumann, J.
    Popat, U. R.
    Kebriaei, P.
    de Lima, M.
    Champlin, R. E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 122 - 122
  • [9] Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial
    Mehta, Rohtesh S.
    Bassett, Roland
    Olson, Amanda
    Chen, Julianne
    Ahmed, Sairah
    Alousi, Amin M.
    Anderlini, Paolo
    Al-Atrash, Gheath
    Bashir, Qaiser
    Ciurea, Stefan O.
    Hosing, Chitra M.
    Im, Jin S.
    Kebriaei, Partow
    Khouri, Issa
    Marin, David
    Molldrem, Jeffrey J.
    Nieto, Yago
    Oran, Betul
    Rezvani, Katayoun
    Qazilbash, Muzaffar H.
    Srour, Samer A.
    Shpall, Elizabeth J.
    Andersson, Borje S.
    Champlin, Richard E.
    Popat, Uday R.
    HAEMATOLOGICA, 2019, 104 (12) : E555 - E557
  • [10] 2ND TRANSPLANTS FOR PATIENTS WITH CHRONIC MYELOID-LEUKEMIA IN RELAPSE AFTER ORIGINAL TRANSPLANT WITH T-DEPLETED DONOR MARROW - FEASIBILITY OF USING BUSULFAN ALONE FOR RE-CONDITIONING
    CULLIS, JO
    SCHWARER, AP
    HUGHES, TP
    HOWS, JM
    FRANKLIN, I
    MORGENSTERN, G
    GOLDMAN, JM
    BRITISH JOURNAL OF HAEMATOLOGY, 1992, 80 (01) : 33 - 39
12